Safety and Efficacy of envudeucitinib, a highly selective, oral allosteric TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis: Results from the 52-week open-label extension period of the Phase 2 STRIDE study

By afschroeder • October 9, 2025

Papp KA, Jacobs S, Sofen H, Bukhalo M, Muscianisi E, Ma G, Lau G, Bettinger M, Rubio RG, Hitraya E, Blauvelt A; Open-Label Extension study team. Safety and Efficacy of envudeucitinib, a highly selective, oral allosteric TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis: Results from the 52-week open-label extension period of the Phase 2 STRIDE study. J Am Acad Dermatol. 2025 Oct 6:S0190-9622(25)02952-4. doi: 10.1016/j.jaad.2025.10.005. Epub ahead of print. PMID: 41061968.

Tags: Dermatology, durability, efficacy, envudeucitinib, ESK-001, long-term extension, Olive View DoM, phase 2, plaque psoriasis, Publications, safety, STRIDE, TYK2

Diagnosis and management of anti-p200 pemphigoid: Perspectives of international dermatologists with expertise in immunobullous diseases

Kasperkiewicz M, Xu J, Thapa M, Culton DA, Curman P, Hashimoto T, Meijer JM, Patsatsi A, Tomayko MM, Lehman JS, Schmidt E. Diagnosis and management[...]

Real-World Effectiveness and Safety of 12 Months of Tralokinumab in Patients with Atopic Dermatitis

Armstrong AW, Ameen A, Ferrucci S, Pereyra-Rodríguez JJ, Cork MJ, Rubin C, Jarell A, Narcisi A, Becherel PA, Beecker J, Festini T, Vittrup I, Vinther[...]

Effectiveness of brodalumab in biologic-experienced adults with moderate to severe plaque psoriasis: a focused narrative review

Armstrong AW, Strober BE, Liu CM, Cather JC, Merola JF, Lebwohl MG. Effectiveness of brodalumab in biologic-experienced adults with moderate to severe plaque psoriasis: a[...]